Gemfibrozil treatment: a comparison with clofibrate.
Gemfibrozil was found to be an effective hypotriglyceridaemic agent in types IV, IIb and V hyperlipoproteinaemia. When given at a dose level of 800 mg/day its activity was nearly of the same order of magnitude as 1.5 g/day of clofibrate.
D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*; D014992:Xylenes / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol; D002994:Clofibrate